Hypoglycemia as first presentation of presumed immune checkpoint inhibitor-induced type 1 diabetes

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Metastatic clear cell renal cell carcinoma (ccRCC) is an advanced form of kidney cancer.
• Immune checkpoint inhibitors like ipilimumab and nivolumab are standard treatments for advanced ccRCC.
• Hypoglycemia is a potential adverse effect of immunotherapy, though rare.

Observation:

• A 60-year-old male patient with metastatic ccRCC received induction therapy with ipilimumab and nivolumab.
• The patient developed symptomatic hypoglycemia during the treatment course.
• Laboratory findings and clinical presentation were consistent with new-onset autoimmune diabetes.

Findings:

• The hypoglycemia was diagnosed as presumed type 1 diabetes mellitus.
• This condition was considered secondary to the ipilimumab and nivolumab immunotherapy.
• This represents a rare instance of immunotherapy-induced endocrinopathy.

Implications:

• Clinicians should be vigilant for endocrine adverse events, including diabetes, during combined ipilimumab and nivolumab therapy.
• Early recognition and management of immunotherapy-related diabetes are crucial for patient safety.
• This case underscores the complex interplay between the immune system and metabolic regulation in cancer patients undergoing immunotherapy.